Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858389 · ClinicalTrials.gov registry record · Phase 2
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01858389 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 41 participants.
The verdict
NCT01858389, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whose tumor has a documented T790M mutation, and those without this mutation. All patients will receive repeated cycles of dacomitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met.
Interventions
- DRUG Dacomitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01858389
The ClinicalTrials.gov registry entry for NCT01858389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dacomitinib is the first listed.
NCT01858389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01858389 about?
NCT01858389 is a clinical study titled "A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer". This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whose tumor has a documented T790M mutation, and those without this mutation. All patients will receive ...
What is the current status of trial NCT01858389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2013-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01858389?
The interventions under investigation include: Dacomitinib (DRUG).
Who is sponsoring clinical trial NCT01858389?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.